Neuronetics(US:STIM)2021-08-03 14:58Company Overview - NeuroStar's mission is renewing lives by transforming neurohealth with its advanced therapy for mental health[8] - NeuroStar is the market leader in TMS for depression, having delivered over 4 million treatment sessions and treated over 110,000 patients[8, 29] - The company has the largest direct sales and customer support team in the industry[8, 48] Clinical and Technological Advantages - NeuroStar delivers proven results with 83% response and 62% remission for patients[21] - The company has clinically proven durability established over 12 months[24] - NeuroStar has patented contact sensing technology for consistent and repeatable treatment[32] - The company possesses a proprietary TrakStar® Data Management System, which includes the world's largest depression outcomes registry with >11,999 patients[34, 35] Market and Financial Performance - The medical industry has relied on pharmaceuticals as the first line treatment for MDD, and 3 out of 5 patients treated with medication are underserved[13] - The estimated total addressable market (TAM) in Japan for treatment sessions is approximately $600 million[61] - Q2 2021 revenue was $142 million, up 46% from Q2 2020's $9741 million[75, 80, 81] - The gross margin for Q2 2021 was 81%, compared to 76% in Q2 2020[83]